SCHEMBL7175448

SCHEMBL7175448

CCCNc1ccccc1-c1cc[c]cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 1/20 0.42
IDO1 P14902 1/20 0.40
GCGR P47871 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.37
MAPT P10636 2/20 0.37
HTT P42858 1/20 0.37
SOAT1 P35610 2/20 0.37
QPCT Q16769 2/20 0.36
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 2/20 0.35
HPGD P15428 1/20 0.35
LMNA P02545 1/20 0.35
BCHE P06276 1/20 0.34
ACHE P22303 1/20 0.34
KCNQ2 O43526 1/20 0.34
ADRA2A P08913 1/20 0.34
ADRA2B P18089 1/20 0.34
ADRA2C P18825 1/20 0.34
MAOA P21397 1/20 0.34
ADRA1D P25100 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7174382 0.86 SMN1; SMN2 (0.42) IDO1SMN1; SMN2MAPTHTTSOAT1
SCHEMBL12984545 0.85 SMN1; SMN2 (0.49) PDE5AIDO1GCGRSMN1; SMN2MAPT
SCHEMBL7186538 0.76 SMN1; SMN2 (0.40) SMN1; SMN2MAPTKDM4EALDH1A1HPGD
SCHEMBL12984564 0.75 SOAT1 (0.53) SMN1; SMN2SOAT1QPCTKDM4EALDH1A1
SCHEMBL27570780 0.75 ALDH1A1 (0.37) SMN1; SMN2MAPTHTTSOAT1KDM4E
SCHEMBL11512622 0.74 IDO1 (0.55) PDE5AIDO1MAPTHTTKDM4E
SCHEMBL1726143 0.74 SOAT1 (0.55) SMN1; SMN2MAPTSOAT1QPCTKDM4E
SCHEMBL9927894 0.74 SOAT1 (0.51) SMN1; SMN2MAPTSOAT1QPCTALDH1A1
SCHEMBL25477578 0.73 MAPT (0.55) PDE5AIDO1GCGRMAPTHTT
SCHEMBL3141420 0.72 KDM1A (0.55) SMN1; SMN2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6576664-B1 1-amido-2-hydroxy-substituted-indanes; suppressing production of tumor necrosis factor BRISTOL-MYERS SQUIBB PHARMA COMPANY 2003-06-10 US disclosed